Treatment of American tegumentary leishmaniasis in special populations: A summary of evidence

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 46, Issue 6, 2013, Pages 669-677

  Silva, Juliana Saboia Fontenele e ^a   Galvao, Tais Freire ^a   Pereira, Maurício Gomes ^a   Silva, Marcus Tolentino ^b  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b Ministério da Saúde   (Brazil)

Author keywords

American tegumentary leishmaniasis; Evidence; Special populations; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; MILTEFOSINE; PENTAMIDINE;

AMERICAN TEGUMENTARY LEISHMANIASIS; ANEMIA; BREAST FEEDING; CARDIOTOXICITY; CHILL; DECISION MAKING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; KIDNEY DISEASE; KIDNEY FAILURE; LEISHMANIASIS; LIVER DISEASE; LIVER TOXICITY; MOTHER; MYELODYSPLASTIC SYNDROME; PANCREATITIS; POSTMARKETING SURVEILLANCE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN LEISHMANIASIS; THROMBOCYTOPENIA; VOMITING;

AGED; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PENTAMIDINE; PHOSPHORYLCHOLINE; PREGNANCY; RISK FACTORS;

EID: 84892682243     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0104-2013     Document Type: Review

References (115)

1. González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010; 51:409-419.
2. Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother 2013; 14:53-63.
3. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 2013; 7:e2130.
4. Reveiz L, Maia-Elkhoury AN, Nicholls RS, Romero GA, Yadon ZE. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS One 2013; 8:e61843.
5. Paniz Mondolfi AE, Duffey GB, Horton LE, Tirado M, Reyes Jaimes O, Perez-Alvarez A, et al. Intermediate/borderline disseminated cutaneous leishmaniasis. Int J Dermatol 2013; 52:446-455.
6. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7:581-596.
7. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis-a systematic review with a meta-analysis. Int J Dermatol 2008; 47:109-124.
8. Mitropoulos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol 2010; 63:309-322.
9. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 2011; 118:87-96.
10. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; CD004834.
11. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-E61.
12. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-1272.
13. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350-356.
14. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210-211.
15. Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:351-356.
16. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912.
17. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, Silva RM, Gadelha Yamashita EP, Oliveira Penna G, et al. Randomized controlled clinical trial to access efficacy and safety of Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255-260.
18. Food and Drug Administration (FDA) Website. U.S. Department of Health & Human Services. FDA; 2011 [cited 2011 Jun 13]. Available at: http://www.fda.gov/default.html.
19. Centers for Disease Control and Prevention (CDC). Leishmania [Internet]. [cited 2011 Jun 10]. Available at: http://www.dpd.cdc.gov/dpdx/HTML/ PDF_Files/MedLetter/Leishmania.pdf.
20. World Health Organization (WHO). Recommendations for drugs in the Eleventh WHO Model List of Essential Drugs 2008 [Internet] [cited 2011 Jun 21]. Available at: http://whqlibdoc.who.int/hq/2002/55732.pdf.
21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
22. Njoku J, Gumeel D, Hermsen E. Antifungal Therapy in Pregnancy and Breastfeeding. Current Fungal Infection Reports. 2010; 4:62-69.
23. Dean JL, Wolf JE, Ranzini AC, Laughlin MA. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18:364-368.
24. Figueiró-Filho EA, El Beitune P, Queiroz GT, Somensi RS, Morais NO, Dorval ME, et al. Visceral leishmaniasis and pregnancy: analysis of cases reported in a central-western region of Brazil. Arch Gynecol Obstet 2008; 278:13-16.
25. Pagliano P, Carannante N, Rossi M, Gramiccia M, Gradoni L, Faella FS, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229-233.
26. Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006; 58:811-815.
27. Léonard A, Gerber GB. Mutagenicity, carcinogenicity and teratogenicity of antimony compounds. Mutat Res 1996; 366:1-8.
28. Paumgartten FJ, Chahoud I. Embryotoxicity of meglumine antimoniate in the rat. Reprod Toxicol 2001; 15:327-331.
29. Miranda ES, Miekeley N, De-Carvalho RR, Paumgartten FJ. Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat. Reprod Toxicol 2006; 21:292-300.
30. Morgan DJ, Guimaraes LH, Machado PR, D'Oliveira A, Almeida RP, Lago EL, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis 2007; 45:478-482.
31. Silveira BP, Araújo Sobrinho J, Leite LF, Sales MN, Gouveia MS, Mathias RL, et al. Premature birth after the use of pentavalent antimonial: case report. Rev Soc Bras Med Trop 2003; 36:523-525.
32. Adam GK, Abdulla MA, Ahmed AA, Adam I. Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan. Int J Gynaecol Obstet 2009; 107:208-210.
33. Ameen M. Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management. Expert Opin Pharmacother 2010; 11:557-569.
34. Minodier P, Jurquet AL, Noël G, Uters M, Laporte R, Garnier JM. Leishmaniasis treatment. Arch Pediatr 2010; 17:838-839.
35. Shukla AK, Singh BK, Patra S, Dubey VK. Rational approaches for drug designing against leishmaniasis. Appl Biochem Biotechnol 2010; 160:2208-2218.
36. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 (suppl I):17-20.
37. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, Vries HJ, Beijnen JH, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855-2860.
38. Dorlo TP, Balasegaram M, Lima MA, Vries PJ, Beijnen JH, Huitema AD. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012; 67:1996-2004.
39. nded. atual. Brasília: Editora do Ministério da Saúde; 2007.
40. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195:602-608.
41. Layegh P, Rahsepar S, Rahsepar AA. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults. Am J Trop Med Hyg 2011; 84:539-542.
42. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-193.
43. Layegh P, Khademi Z, Kiafar B. Side effects of systemic meglumine antimoniate in children with cutaneo us leishmaniasis: A prospective clinico-laborator y assess. Euro J Pediatric Dermatol 2012; 22:15.
44. Garcerant D, Rubiano L, Blanco V, Martinez J, Baker NC, Craft N. Possible links between sickle cell crisis and pentavalent antimony. Am J Trop Med Hyg 2012; 86:1057-1061.
45. Gadelha AR, Oliveira WC, Assunção IJ, Dourado HV. Tratamento da leishmaniose tegumentar americana com injeções intralesionais de n-metil-glucamina. An Bras Dermatol 1990; 65:201.
46. Campos-Muñoz L, Quesada-Cortés A, Martín-Díaz MA, Rubio-Flores C, Lucas-Laguna R. Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B. Actas Dermosifiliogr 2007; 98:42-44.
47. Rosal T, Artigao FB, Miguel MJ, Lucas R, Castillo F. Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. J Trop Pediatr 2010; 56:122-124.
48. Sampaio RN, Paula CD. American cutaneous leishmaniasis in the Federal District. Rev Soc Bras Med Trop 1999; 32:523-528.
49. Neves LO, Talhari AC, Gadelha EP, Silva Júnior RM, Guerra JA, Ferreira LC, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011; 86:1092-1101.
50. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205:684-692.
51. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003;16:397-401.
52. Diniz DS, Costa AS, Escalda PM. The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2012; 45:597-600.
53. Araujo-Melo MH, Meneses AM, Schubach AO, Moreira JS, Conceição-Silva F, Salgueiro MM, et al. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil. J Laryngol Otol 2010; 124:1056-1060.
54. Vasconcellos ECF, Schubach AO, Valete-Rosalino CM, Coutinho RS, Conceição-Silva F, Salgueiro MM, et al. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil. J Am Geriatr Soc 2010; 58:614-616.
55. Rodrigues AM, Hueb M, Nery AF, Fontes CJ. Possible cardioprotective effect of angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with meglumine antimoniate. Acta Trop 2007; 102:113-118.
56. Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol 2012; 51:1221-1225.
57. Vasconcellos EC, Pimentel MI, Schubach AO, Oliveira RV, Azeredo-Coutinho RB, Silva FC, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg 2012; 87:257-260.
58. Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]. PLoS Negl Trop Dis 2012; 6:e1688.
59. Neumayr AL, Walter C, Stoeckle M, Braendle N, Glatz K, Blum JA. Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment. J Travel Med 2012; 19:124-126.
60. Oliveira RA, Lima CG, Mota RM, Martins AM, Sanches TR, Seguro AC, et al. Renal function evaluation in patients with American cutaneous leishmaniasis after specific treatment with pentavalent antimonial. BMC Nephrol 2012; 13:44.
61. Brostoff JM, Lockwood DN. Glucocorticoids as a novel approach to the treatment of disabling side effects of sodium stibogluconate. J Clin Pharm Ther 2012; 37:122-123.
62. Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop 2004; 92:127-132.
63. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528-534.
64. Oliveira MJ, Silva Júnior GB, Abreu KL, Rocha NA, Garcia AV, Franco LF, et al. Risk factors for acute kidney injury in visceral leishmaniasis (Kala-Azar). Am J Trop Med Hyg 2010; 82:449-453.
65. Mistro S, Maciel IM, Menezes RG, Maia ZP, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 2012; 54:1774-1777.
66. Echevarria J, Seas C, Cruz M, Chávez E, Campos M, Cieza J, et al. Oral rehydration solution to prevent nephrotoxicity of amphotericin B. Am J Trop Med Hyg 2006; 75:1108-1112.
67. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995; 70:235-241.
68. Zea DF, Prager M, Figueroa RA, Miranda MC. Mucosal complication of cutaneous leishmaniasis. Biomédica 2009; 29:9-11.
69. National Vector Borne Disease Control Programme (NVBDCP) [Internet]. Guidelines on use of miltefosine [Cited 2011 Jun 10]. Available at: http:// nvbdcp.gov.in/Doc/Guidelines%20on%20miltefosine.pdf.
70. Clementi A, Battaglia G, Floris M, Castellino P, Ronco C, Cruz DN. Renal involvement in leishmaniasis: A review of the literature. NDT Plus 2011; 4:147-152.
71. Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore 2008; 37:916-918.
72. Eryilmaz A, Durdu M, Baba M, Bal N, Yiǧit F. A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy. Int J Dermatol 2010; 49:295-297.
73. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 1991; 164:418-421.
74. Unger C, Fleer E, Damenz W, Hilgard P, Nagel G, Eibl H. Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat 1991; 3:71-78.
75. Machado ES, Braga MP, Cruz AM, Coutinho SG, Vieira AR, Rutowitsch MS, et al. Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report. Mem Inst Oswaldo Cruz 1992; 87:487-492.
76. Amato VS, Nicodemo AC, Amato JG, Boulos M, Amato-Neto V. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 2000; 46:341-342.
77. Murray HW. Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000; 44:3235-3236.
78. Sampaio RN, Salaro CP, Resende P, de Paula CD. American cutaneous leishmaniasis associated with HIV/AIDS: report of four clinical cases. Rev Soc Bras Med Trop 2002; 35:651-654.
79. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol 2003; 97 (suppl I):107-114.
80. Couppié P, Clyti E, Sobesky M, Bissuel F, Del Giudice P, Sainte-Marie D, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165-1171.
81. Sindermann H, Engel KR, Fischer C, Bommer W, Program MCU. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39:1520-1523.
82. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192:1819-1822.
83. Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005; 40:e120-124.
84. Sinha S, Fernández G, Kapila R, Lambert WC, Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 2008; 47:1263-1270.
85. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, Silva RM, Ferreira LC, Botileiro SF, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009; 81:559-564.
86. Lindoso JA, Barbosa RN, Posada-Vergara MP, Duarte MI, Oyafuso LK, Amato VS, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 2009; 160:311-318.
87. Torrico F, Parrado R, Castro R, Marquez CJ, Torrico MC, Solano M, et al. Co-Infection of Leishmania (Viannia) braziliensis and HIV: report of a case of mucosal leishmaniasis in Cochabamba, Bolivia. Am J Trop Med Hyg 2009; 81:555-558.
88. Soni P, Prasad N, Khandelwal K, Ghiya BC, Mehta RD, Bumb RA, et al. Unresponsive cutaneous leishmaniasis and HIV co-infection: report of three cases. Indian J Dermatol Venereol Leprol 2011; 77:251.
89. Gontijo CM, Pacheco RS, Orefice F, Lasmar E, Silva ES, Melo MN. Concurrent cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis in a kidney transplant patient. Mem Inst Oswaldo Cruz 2002; 97:751-753.
90. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol 2006; 33:701-704.
91. Ozcan D, Seçkin D, Allahverdiyev AM, Weina PJ, Aydin H, Ozçay F, et al. Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis. Pediatr Transplant 2007; 11:228-232.
92. Antinori S, Schifanella L, Corbellino M. Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis 2012; 31:109-118.
93. Zandieh A, Zandieh B, Dastgheib L. Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. Int J Dermatol 2013; 52:59-62.
94. Muñoz P, Valerio M, Puga D, Bouza E. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am 2010; 24:461-495.
95. Ponticelli C, Bencini PL. Nonneoplastic mucocutaneous lesions in organ transplant recipients. Transpl Int 2011; 24:1041-1050.
96. Saha M, Shipley D, McBride S, Kennedy C, Vega-Lopez F. Atypical cutaneous leishmaniasis in two patients receiving low-dose methotrexate. Br J Dermatol 2006; 155:830-833.
97. Tuon FF, Sabbaga Amato V, Floeter-Winter LM, Andrade Zampieri R, Amato Neto V, Siqueira França FO, et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids-first report. Int J Dermatol 2007; 46:628-630.
98. Pitini V, Cascio A, Arrigo C, Altavilla G. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 2012; 156:1.
99. Guerra JA, Coelho LI, Pereira FR, Siqueira AM, Ribeiro RL, Almeida TM, et al. American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. Am J Trop Med Hyg 2011; 85:524-527.
100. Amerson EH, Maurer TA. Immune reconstitution inflammatory syndrome and tropical dermatoses. Dermatol Clin 2011; 29:39-43.
101. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334-359.
102. Alexandrino-de-Oliveira P, Santos-Oliveira JR, Dorval ME, Da-Costa F, Pereira GR, Cunha RV, et al. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil. Mem Inst Oswaldo Cruz 2010; 105:692-697.
103. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011; 85: 818-819.
104. Soto J, Soto P. Oral miltefosine to treat leishmaniasis. Biomedica 2006; 26 (supl I):207-217.
105. Pérez C, Solías Y, Rodríguez G. Diffuse cutaneous leishmaniasis in a patient with AIDS. Biomedica 2006; 26:485-497.
106. Kotton CN, Lattes R, Practice AIDCo. Parasitic infections in solid organ transplant recipients. Am J Transplant. 2009; 9 (suppl IV):234-251.
107. Simon I, Wissing KM, Del Marmol V, Antinori S, Remmelink M, Nilufer Broeders E, et al. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transpl Infect Dis 2011; 13:397-406.
108. Bacha MM, Abderrahim E, Ounissi M, Chaouech D, Cherif M, Turki S, et al. Association of post-transplant lymphoproliferative disease and visceral leishmaniasis after kidney transplantation. Nephrol Ther 2011; 7:488-493.
109. Postorino MC, Bellantoni M, Catalano C, Caridi G, Rosa M, Seck S, et al. Visceral leishmaniasis reactivation in transplant patients: a minireview with report of a new case. J Nephrol 2011; 24:530-534.
110. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome). Clin Infect Dis 1999; 28:1308-1309.
111. Bousquet E, Mura F, Villain M, Rivière S, Konate A, Schneider C. Infectious complications in patients treated with anti-TNF-alpha: two cases of leishmaniasis. J Fr Ophtalmol 2012; 35:695-699.
112. Prokopakis EP, Panagiotaki IE, Papadakis IA, Vardouniotis AS, Lagoudianakis GM, Velegrakis GA. Immunocompromised patient with an ulcerated nasolabial skin lesion. BMJ 2010; 340:c1444.
113. Veroux M, Corona D, Giuffrida G, Cacopardo B, Sinagra N, Tallarita T, et al. Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management. Transpl Infect Dis 2010; 12:387-391.
114. Frapier JM, Abraham B, Dereure J, Albat B. Fatal visceral leishmaniasis in a heart transplant recipient. J Heart Lung Transplant 2001; 20:912-913.
115. Sindermann H, Croft SL, Engel KR, Bommer W, Eibl HJ, Unger C, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol 2004; 193:173-180.